FBXO22 and lung carcinoma: Deguelin was identified as a functional inhibitor of FBXO22 by utilizing the CMap database and was shown to increase lung cancer radiosensitivity in vitro and in vivo with a favorable safety profile, exhibiting substantial clinical translation prospects.